284 related articles for article (PubMed ID: 16378996)
21. Antigenic and immunogenic characterization of recombinant baculovirus-expressed severe acute respiratory syndrome coronavirus spike protein: implication for vaccine design.
He Y; Li J; Heck S; Lustigman S; Jiang S
J Virol; 2006 Jun; 80(12):5757-67. PubMed ID: 16731915
[TBL] [Abstract][Full Text] [Related]
22. Conserved amino acids W423 and N424 in receptor-binding domain of SARS-CoV are potential targets for therapeutic monoclonal antibody.
Bian C; Zhang X; Cai X; Zhang L; Chen Z; Zha Y; Xu Y; Xu K; Lu W; Yan L; Yuan J; Feng J; Hao P; Wang Q; Zhao G; Liu G; Zhu X; Shen H; Zheng B; Shen B; Sun B
Virology; 2009 Jan; 383(1):39-46. PubMed ID: 18986662
[TBL] [Abstract][Full Text] [Related]
23. Human monoclonal antibodies against highly conserved HR1 and HR2 domains of the SARS-CoV spike protein are more broadly neutralizing.
Elshabrawy HA; Coughlin MM; Baker SC; Prabhakar BS
PLoS One; 2012; 7(11):e50366. PubMed ID: 23185609
[TBL] [Abstract][Full Text] [Related]
24. Evaluation of human monoclonal antibody 80R for immunoprophylaxis of severe acute respiratory syndrome by an animal study, epitope mapping, and analysis of spike variants.
Sui J; Li W; Roberts A; Matthews LJ; Murakami A; Vogel L; Wong SK; Subbarao K; Farzan M; Marasco WA
J Virol; 2005 May; 79(10):5900-6. PubMed ID: 15857975
[TBL] [Abstract][Full Text] [Related]
25. Structural basis for potent cross-neutralizing human monoclonal antibody protection against lethal human and zoonotic severe acute respiratory syndrome coronavirus challenge.
Rockx B; Corti D; Donaldson E; Sheahan T; Stadler K; Lanzavecchia A; Baric R
J Virol; 2008 Apr; 82(7):3220-35. PubMed ID: 18199635
[TBL] [Abstract][Full Text] [Related]
26. Single amino acid substitutions in the severe acute respiratory syndrome coronavirus spike glycoprotein determine viral entry and immunogenicity of a major neutralizing domain.
Yi CE; Ba L; Zhang L; Ho DD; Chen Z
J Virol; 2005 Sep; 79(18):11638-46. PubMed ID: 16140741
[TBL] [Abstract][Full Text] [Related]
27. Immunogenicity of SARS-CoV: the receptor-binding domain of S protein is a major target of neutralizing antibodies.
He Y
Adv Exp Med Biol; 2006; 581():539-42. PubMed ID: 17037594
[No Abstract] [Full Text] [Related]
28. Template-based coiled-coil antigens elicit neutralizing antibodies to the SARS-coronavirus.
Tripet B; Kao DJ; Jeffers SA; Holmes KV; Hodges RS
J Struct Biol; 2006 Aug; 155(2):176-94. PubMed ID: 16697221
[TBL] [Abstract][Full Text] [Related]
29. Identification of two neutralizing regions on the severe acute respiratory syndrome coronavirus spike glycoprotein produced from the mammalian expression system.
Wang S; Chou TH; Sakhatskyy PV; Huang S; Lawrence JM; Cao H; Huang X; Lu S
J Virol; 2005 Feb; 79(3):1906-10. PubMed ID: 15650214
[TBL] [Abstract][Full Text] [Related]
30. Recombinant modified vaccinia virus Ankara expressing the spike glycoprotein of severe acute respiratory syndrome coronavirus induces protective neutralizing antibodies primarily targeting the receptor binding region.
Chen Z; Zhang L; Qin C; Ba L; Yi CE; Zhang F; Wei Q; He T; Yu W; Yu J; Gao H; Tu X; Gettie A; Farzan M; Yuen KY; Ho DD
J Virol; 2005 Mar; 79(5):2678-88. PubMed ID: 15708987
[TBL] [Abstract][Full Text] [Related]
31. Immunological characterization of the spike protein of the severe acute respiratory syndrome coronavirus.
Lu L; Manopo I; Leung BP; Chng HH; Ling AE; Chee LL; Ooi EE; Chan SW; Kwang J
J Clin Microbiol; 2004 Apr; 42(4):1570-6. PubMed ID: 15071006
[TBL] [Abstract][Full Text] [Related]
32. Fully human monoclonal antibody directed to proteolytic cleavage site in severe acute respiratory syndrome (SARS) coronavirus S protein neutralizes the virus in a rhesus macaque SARS model.
Miyoshi-Akiyama T; Ishida I; Fukushi M; Yamaguchi K; Matsuoka Y; Ishihara T; Tsukahara M; Hatakeyama S; Itoh N; Morisawa A; Yoshinaka Y; Yamamoto N; Lianfeng Z; Chuan Q; Kirikae T; Sasazuki T
J Infect Dis; 2011 Jun; 203(11):1574-81. PubMed ID: 21592986
[TBL] [Abstract][Full Text] [Related]
33. Monoclonal antibodies to SARS-associated coronavirus (SARS-CoV): identification of neutralizing and antibodies reactive to S, N, M and E viral proteins.
Tripp RA; Haynes LM; Moore D; Anderson B; Tamin A; Harcourt BH; Jones LP; Yilla M; Babcock GJ; Greenough T; Ambrosino DM; Alvarez R; Callaway J; Cavitt S; Kamrud K; Alterson H; Smith J; Harcourt JL; Miao C; Razdan R; Comer JA; Rollin PE; Ksiazek TG; Sanchez A; Rota PA; Bellini WJ; Anderson LJ
J Virol Methods; 2005 Sep; 128(1-2):21-8. PubMed ID: 15885812
[TBL] [Abstract][Full Text] [Related]
34. Neutralizing human monoclonal antibodies to severe acute respiratory syndrome coronavirus: target, mechanism of action, and therapeutic potential.
Coughlin MM; Prabhakar BS
Rev Med Virol; 2012 Jan; 22(1):2-17. PubMed ID: 21905149
[TBL] [Abstract][Full Text] [Related]
35. Identification and antigenic epitope mapping of immunodominant region amino residues 510 to 672 on the spike protein of the severe acute respiratory syndrome coronavirus.
Hua RH; Wang YF; Bu ZG; Zhou YJ; Ge JY; Wang XJ; Tong GZ
DNA Cell Biol; 2005 Aug; 24(8):503-9. PubMed ID: 16101348
[TBL] [Abstract][Full Text] [Related]
36. Involvement in fusion activity of an epitope in the S2 subunit of murine coronavirus spike protein.
Taguchi F; Shimazaki YK
Adv Exp Med Biol; 2001; 494():213-8. PubMed ID: 11774471
[No Abstract] [Full Text] [Related]
37. B-cell responses in patients who have recovered from severe acute respiratory syndrome target a dominant site in the S2 domain of the surface spike glycoprotein.
Zhong X; Yang H; Guo ZF; Sin WY; Chen W; Xu J; Fu L; Wu J; Mak CK; Cheng CS; Yang Y; Cao S; Wong TY; Lai ST; Xie Y; Guo Z
J Virol; 2005 Mar; 79(6):3401-8. PubMed ID: 15731234
[TBL] [Abstract][Full Text] [Related]
38. Solution structure of the severe acute respiratory syndrome-coronavirus heptad repeat 2 domain in the prefusion state.
Hakansson-McReynolds S; Jiang S; Rong L; Caffrey M
J Biol Chem; 2006 Apr; 281(17):11965-71. PubMed ID: 16507566
[TBL] [Abstract][Full Text] [Related]
39. Epitope mapping and biological function analysis of antibodies produced by immunization of mice with an inactivated Chinese isolate of severe acute respiratory syndrome-associated coronavirus (SARS-CoV).
Chou TH; Wang S; Sakhatskyy PV; Mboudjeka I; Lawrence JM; Huang S; Coley S; Yang B; Li J; Zhu Q; Lu S
Virology; 2005 Mar; 334(1):134-43. PubMed ID: 15749129
[TBL] [Abstract][Full Text] [Related]
40. Mapping a neutralizing epitope on the SARS coronavirus spike protein: computational prediction based on affinity-selected peptides.
Tarnovitski N; Matthews LJ; Sui J; Gershoni JM; Marasco WA
J Mol Biol; 2006 May; 359(1):190-201. PubMed ID: 16630634
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
